Vaccines comprising a polysaccharide antigen-carrier protein conjugate and free carrier protein

(19)

(11)

EP 1 090 642 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	11.08.2010 Bulletin 2010/32

(45)	Mention of the grant of the patent:
	09.07.2008 Bulletin 2008/28

(21)	Application number: 00203772.9

(22)	Date of filing: 04.06.1996

(51)

International Patent Classification (IPC):

A61K 39/385^(2006.01)
A61K 39/295^(2006.01)
A61P 31/00^(2006.01)

A61K 39/116^(2006.01)
A61K 39/00^(2006.01)

(54)	Vaccines comprising a polysaccharide antigen-carrier protein conjugate and free carrier protein Vakzine mit einem Polysaccharide Antigen-Trägerprotein Konjugat und freiem Trägerprotein Vaccins comprenant un conjugué antigènique de polysaccharide-protéine porteuse et une protéine porteuse libre

(84)	Designated Contracting States:
	AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
	Designated Extension States:
	SI

(30)

Priority:

07.06.1995 US 472639
23.06.1995 GB 9512827
01.07.1995 GB 9513443
15.12.1995 GB 9525657

(43)	Date of publication of application:
	11.04.2001 Bulletin 2001/15

(62)	Application number of the earlier application in accordance with Art. 76 EPC:
	96920790.1 / 0831901

(73)	Proprietor: GlaxoSmithKline Biologicals s.a.
	1330 Rixensart (BE)

(72)	Inventors:
	Slaoui, Moncef Mohamed, SmithKline Beecham Biol.SA 1330 Rixensart (BE) Hauser, Pierre, SmithKline Beecham Biologicals S.A 1330 Rixensart (BE)

(74)	Representative: Privett, Kathryn Louise et al
	GlaxoSmithKline, Corporate Intellectual Property (CN9.25.1), 980 Great West Road Brentford, Middlesex TW8 9GS Brentford, Middlesex TW8 9GS (GB)

(56)

References cited: :

EP-A- 0 208 375
US-A- 4 644 059

EP-A- 0 594 950

BARINGTON, T. ET AL.: "Opposite effects of actively and passively acquired immunity to the carrier on responses of human infants to a Haemophilus influenzae type b conjugate vaccine" INFECTION AND IMMUNITY, vol. 62, 1994, pages 9-14, XP000602292
CORBEL, M.J.: "Control testing of combined vaccines: a consideration of potential problems and approches" BIOLOGICALS, vol. 22, 1994, pages 353-360, XP000603003
BÉGUÉ, P.: "Vaccins haemophilus influenzae" BULLETIN DE L'ACADÉMIE NATIONALE DE MÉDECINE, vol. 177, 1993, pages 1381-1387, XP000602905
BARINGTON, T. ET AL.: "Non-epitope-specific suppression of the antibody response to Haemophilus influenzae type b conjugate vaccines by preimmunization with vaccine components" INFECTION AND IMMUNITY, vol. 61, 1993, pages 432-438, XP000602293
FRASCH, C.E.: "Haemophilus influenzae type b conjugate and combination vaccines" CLINICAL IMMUNOTHERAPEUTICS, vol. 4, November 1995 (1995-11), pages 376-386, XP000602898

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).